Loading...
Please wait, while we are loading the content...
Similar Documents
Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project
| Content Provider | MDPI |
|---|---|
| Author | Grettel, Chanto Chacón Maria, León Lucia, Mad’Arová Anna, Skoczyńska Knoll, Maria Deloria Bennett, Julia Quesada, Maria Garcia Kagucia, Eunice Peterson, Meagan Feikin, Daniel Cohen, Adam Hetrich, Marissa Yang, Yangyupei Sinkevitch, Jenna Ampofo, Krow Aukes, Laurie Bacci, Sabrina Bigogo, Godfrey Brandileone, Maria-Cristina Bruce, Michael Camilli, Romina Castilla, Jesús Chan, Guanhao Ciruela, Pilar Cook, Heather Corcoran, Mary Dagan, Ron Danis, Kostas de Miguel, Sara Wals, Philippe De Desmet, Stefanie Galloway, Yvonne Georgakopoulou, Theano Hammitt, Laura Hilty, Markus Ho, Pak-Leung Jayasinghe, Sanjay Kellner, James Kleynhans, Jackie Knol, Mirjam Kozakova, Jana Kristinsson, Karl Ladhani, Shamez Lara, Claudia Lepp, Tiia Mackenzie, Grant McGeer, Allison Mungun, Tuya Mwenda, Jason Nuorti, J. Nzoyikorera, Néhémie Oishi, Kazunori Oliveira, Lucia De Paragi, Metka Pilishvili, Tamara Puentes, Rodrigo Rafai, Eric Saha, Samir Savrasova, Larisa Savulescu, Camelia Scott, J. Scott, Kevin Serhan, Fatima Setchanova, Lena Zorko, Nadja Sinkovec Swarthout, Todd Valentiner-Branth, Palle van der Linden, Mark Vestrheim, Didrik von Gottberg, Anne Yildirim, Inci Hayford, Kyla |
| Copyright Year | 2021 |
| Description | Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon. |
| Starting Page | 742 |
| e-ISSN | 20762607 |
| DOI | 10.3390/microorganisms9040742 |
| Journal | Microorganisms |
| Issue Number | 4 |
| Volume Number | 9 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-04-02 |
| Access Restriction | Open |
| Subject Keyword | Microorganisms Infectious Diseases Global Invasive Pneumococcal Disease Pneumococcal Meningitis Surveillance Pneumococcal Conjugate Vaccines |
| Content Type | Text |
| Resource Type | Article |
